Rare sugars: metabolic impacts and mechanisms of action: a scoping review. Issue 3 (14th August 2022)

• Record Type: Journal Article
• Authors: Smith, Alison; Avery, Amanda; Ford, Rebecca; Yang, Qian; Goux, Aurélie; Mukherjee, Indraneil; Neville, David C. A.; Jethwa, Preeti
• Is Part Of: British journal of nutrition. Volume 128:Issue 3(2022)
• Page Start: 389
• Page End: 406
• Publication Date: 2022-08-14
• Subjects: Rare sugar -- d-psicose -- d-tagatose -- Type 2 diabetes -- Obesity; Nutrition -- Periodicals; 572.4
• DOI: 10.1017/S0007114521003524
• Languages: English
• ISSNs: 0007-1145

Abstract

Abstract : Abstract: Food manufacturers are under increasing pressure to limit the amount of free sugars in their products. Many have reformulated products to replace sucrose, glucose and fructose with alternative sweeteners, but some of these have been associated with additional health concerns. Rare sugars are 'monosaccharides and their derivatives that hardly exist in nature', and there is increasing evidence that they could have health benefits. This review aimed to scope the existing literature in order to identify the most commonly researched rare sugars, to ascertain their proposed health benefits, mechanisms of action and potential uses and to highlight knowledge gaps. A process of iterative database searching identified fifty-five relevant articles. The reported effects of rare sugars were noted, along with details of the research methodologies conducted. Our results indicated that the most common rare sugars investigated are d -psicose and d -tagatose, with the potential health benefits divided into three topics: glycaemic control, body composition and CVD. All the rare sugars investigated have the potential to suppress postprandial elevation of blood glucose and improve glycaemic control in both human and animal models. Some animal studies have suggested that certain rare sugars may also improve lipid profiles, alter the gut microbiome and reduce pro-inflammatory cytokine expression. The present review demonstrates that rare sugars could play a role in reducing the development of obesity, type 2 diabetes and/or CVD. However, understanding of the mechanisms by which rare sugars may exert their effects is limited, and their effectiveness when used in reformulated products is unknown.